SP 420
Alternative Names: SP-420Latest Information Update: 10 Jan 2025
At a glance
- Originator University of Florida
- Developer Pharmacosmos; Sideris Pharmaceuticals
- Class Small molecules
- Mechanism of Action Iron chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Iron overload
Most Recent Events
- 20 Dec 2024 The University of Texas Health Science Center at San Antonio and Abfero Pharmaceuticals terinatess a phase I trial in Iron overload in the US due to hold on the study by FDA in US (PO) (NCT04741542)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Iron-overload in USA (PO)
- 06 Dec 2023 The University of Texas Health Science Center at San Antonio and Abfero Pharmaceuticals suspends a phase I trial in Iron overload in the US due to hold on the study by FDA in US (PO) (NCT04741542) .